Global pharma firm spanning radiopharma, allergy immunotherapy, sterile-injectable CDMO, CRDMO and generics.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 5.6k | 4.7k | 5.3k | 5.4k | 5.4k | 6.2k | 6.6k | 7.1k |
| Borrowings | 4.8k | 2.8k | 3.2k | 3.7k | 3.7k | 2.7k | 2.9k | 3.6k |
| Other Liabilities | 1.9k | 1.2k | 1.3k | 1.9k | 2.2k | 3.6k | 4.0k | 4.8k |
| Total Liabilities | 12.3k | 8.8k | 9.8k | 10.9k | 11.3k | 12.6k | 13.5k | 15.5k |
| AssetsFixed Assets | 6.3k | 4.6k | 4.9k | 5.2k | 5.1k | 5.2k | 7.4k | 8.0k |
| CWIP | 768 | 897 | 1.1k | 1.6k | 2.1k | 3.6k | 2.3k | 3.0k |
| Investments | 69 | 241 | 239 | 256 | 42 | 44 | 45 | 61 |
| Other Assets | 5.1k | 3.0k | 3.6k | 3.9k | 4.1k | 3.7k | 3.8k | 4.5k |
| Total Assets | 12.3k | 8.8k | 9.8k | 10.9k | 11.3k | 12.6k | 13.5k | 15.5k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 1.1k | 1.5k | 1.8k | 838 | 661 | 971 | 1.1k | 1.2k |
| Cash from Investing | -1.0k | -267 | -727 | -323 | -474 | -596 | 512 | -1.3k |
| Cash from Financing | 657 | -1.1k | -1.7k | -33 | -157 | -432 | -1.5k | 95 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 473 | 975 | 1.3k | 241 | -135 | 83 | -38 | -120 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
JUBLPHARMA · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.